Focused Disease Areas for a Stronger Business Model

แชร์
ฝัง
  • เผยแพร่เมื่อ 29 ม.ค. 2024
  • A Novartis focused disease areas strategy with supporting commercial strength was outlined for investors at 2024 J.P. Morgan Healthcare Conference.
    A strategy focused on core therapeutic areas where we have strong R&D, brands and commercial experience enables us to deliver high-value medicines that alleviate society’s greatest disease burdens. Our CEO, Vas Narasimhan provides an overview of these areas (cardiovascular, renal & metabolic, oncology, immunology and neuroscience) and the business foundations to support.
    *This video uses audio from the webcasted event.*
    J.P. Morgan Healthcare Conference
    Event Date: January 08, 2024
    Full webcast here: go.novartis.social/49012mq
    Full presentation here: go.novartis.social/42lZfpC
    Novartis JPM HC 2024 Coverage: go.novartis.social/3SAAJy0
    Investor Relations: go.novartis.social/3SBMpjR
    Investor Events: go.novartis.social/4813eJr
    Novartis Strategy: go.novartis.social/3HEGx3d
    Disclaimer: J.P. Morgan Healthcare Conference live event contains forward-looking statements. Such forward-looking statements are subject to significant known and unknown risks and uncertainties. Visit our website for more information: go.novartis.social/49dXdKx
    The J.P. Morgan Healthcare conference live event also contains non-IFRS measures. An explanation of non-IFRS measures can be found on our website go.novartis.social/47UDpLa.
    Learn more: go.novartis.social/3SAAJy0
  • วิทยาศาสตร์และเทคโนโลยี

ความคิดเห็น •